{"id":"NCT01569841","sponsor":"Novo Nordisk A/S","briefTitle":"A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes","officialTitle":"A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-04","primaryCompletion":"2012-11","completion":"2012-11","firstPosted":"2012-04-03","resultsPosted":"2015-11-17","lastUpdate":"2016-02-18"},"enrollment":24,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes","Diabetes Mellitus, Type 1"],"interventions":[{"type":"DRUG","name":"insulin degludec","otherNames":[]},{"type":"DRUG","name":"insulin glargine","otherNames":[]}],"arms":[{"label":"IDeg","type":"EXPERIMENTAL"},{"label":"IGlar","type":"ACTIVE_COMPARATOR"}],"summary":"This trial is conducted in the United States of America (USA). The aim of this trial is to compare the efficacy of insulin decludec with insulin glargine on glycaemic control using continuous glucose monitoring in patients with type 1 diabetes.","primaryOutcome":{"measure":"Average Time Within Glycaemic Target Range (Above 70 mg/dL and Below 130 mg/dL)","timeFrame":"CGM occured during the last 2 weeks of the 6 weeks treatment period.","effectByArm":[{"arm":"IDeg","deltaMin":1.39,"sd":0.71},{"arm":"IGlar","deltaMin":1.09,"sd":0.77}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":23},"commonTop":["Nasopharyngitis"]}}